Background: Very low birth weight (VLBW) infants are susceptible to glutamine depletion. Glutamine depletion has negative effects on intestinal integrity. The lower infection rate in VLBW infants receiving glutamine-enriched enteral nutrition may originate from improved intestinal integrity, as reflected by decreased intestinal permeability. The aim of our study was to investigate whether glutamine-enriched enteral nutrition in VLBW infants enhances the normal decrease in intestinal permeability, as measured by the sugar absorption test (SAT). Methods: In a doubleblind, randomized, placebo-controlled trial, VLBW infants (gestational age <32 weeks or birth weight <1500 g) received enteral glutamine supplementation (0.3 g/kg/d) or an isonitrogenous placebo supplementation (alanine) between days 3 and 30 of life. Intestinal permeability, determined from the urinary lactulose/mannitol (L/M) ratio after an oral dose of lactulose and mannitol, was assessed at 4 time points: before the start of the study, and at days 7, 14, and 30 of life. Results: At least 2 SATs were performed in 45/52 (86%) and 45/50 (90%) infants in the glutamine-supplemented and control groups, respectively. Baseline patient and nutrition characteristics were not different between the groups. There was no effect of glutamine-enriched enteral nutrition on the decrease of the L/M ratio between the start and end of the study (p = 0.78). In both treatment groups, median urinary lactulose concentrations decreased (p <0.001), whereas median urinary mannitol concentrations increased (p = 0.03). Conclusions: Glutamine-enriched enteral nutrition does not enhance the postnatal decrease in intestinal permeability in VLBW infants. Any beneficial effect of glutamine may involve other aspects of intestinal integrity; for example, modulation of the intestinal inflammatory response.
Introduction
Very low birth weight (VLBW) infants are susceptible to glutamine depletion because placental supply ceases at birth, tolerance of enteral nutrition is limited, and parenteral nutrition does not contain glutamine for solubility and stability reasons. In recent studies in VLBW infants, Neu et al. 8 and our group (chapter 2) have found that glutamine-enriched enteral nutrition between days 3 and 30 of life decreased the incidence of serious infections. Other studies of enteral 42 and parenteral 39,40 glutamine supplementation in VLBW infants could not confirm this finding, possibly because of differences in supplementation method, supplementation dose, and definition of infections.
As shown in studies of animals and adults, one suggested mechanism of the beneficial effect of glutamine is its role in maintaining functional integrity of the gut. 2, 4, 5, 9, 10 It has been shown that depletion of dietary or endogenously synthesized glutamine has a negative effect on the integrity of intestinal epithelium.
11 Furthermore, glutamine supplementation reduces intestinal atrophy and decreases intestinal permeability after parenteral nutrition, 12,13 abdominal radiation, 14 and pharmacologic agents. 15, 16 It is assumed that improved intestinal integrity leads to decreased bacterial translocation, 70, 71 decreased systemic spread of bacteria, 72 and consequently to decreased infectious morbidity. One study in adult burn patients found that increased intestinal permeability was associated with increased infectious morbidity. 84 In another study, burn patients who developed clinical infections had a greater increase in intestinal permeability than patients who did not develop infections. 85 Studies of glutamine supplementation in adults have found varying effects on intestinal permeability and integrity of the intestinal epithelium. [17] [18] [19] [20] [21] [22] Two studies, one in critically ill adults 17 and the other in patients with various gastroenterologic diseases, 18 have found that glutamine supplementation did not decrease intestinal permeability. However, other studies in healthy volunteers, 19 critically ill patients, 20, 21 and various patients receiving parenteral nutrition 22 have shown that glutamine supplementation has a beneficial effect on intestinal permeability and mucosal structure.
Until now, the effect of enteral glutamine supplementation on the intestinal permeability in VLBW infants has not been studied. In VLBW infants, intestinal permeability was found to decrease spontaneously in the first week of life. 23, 86 We hypothesized that the previously found lower infection rate in VLBW infants receiving glutamine-enriched enteral nutrition might originate from improved intestinal integrity, as reflected by decreased intestinal permeability. For this reason, as part of the aforementioned double-blinded, placebo-controlled, randomized controlled trial of glutamine-enriched enteral nutrition in VLBW infants (chapter 2), intestinal permeability was assessed throughout a 30-day study period.
Materials and methods

Patients
All infants with a gestational age (GA) <32 weeks or birth weight (BW) <1500 g admitted to the level III neonatal intensive care unit (NICU) of the VU University Medical Center, Amsterdam, were eligible for participation in the study. Exclusion criteria were major congenital or chromosomal anomalies, death within 48 hours after birth, transfer to another hospital within 48 hours after birth, and admission from an extraregional hospital. The national central committee on research involving human subjects and the medicalethical review board of our hospital approved the study protocol. Written informed consent was obtained from all parents.
Study Design Randomization, blinding and treatment. After assignment to 1 of 3 BW strata (≤799 g, 800-1199 g, ≥1200 g), infants were randomly allocated within 48 hours after birth to receive enteral glutamine supplementation or isonitrogenous control supplementation. An independent researcher used a computer-generated randomization table based on blocks of 4 (provided by Nutricia Nederland BV, Zoetermeer, The Netherlands) to assign infants to treatment A or B, which corresponded to batch numbers on the nutrition products. Investigators, parents, and medical and nursing staff were unaware of treatment allocation. The code for the batch numbers was broken after data analysis had been performed.
Glutamine powder contained 82% L-Glutamine and 18% glucose (nitrogen, 15.5 wt/wt%; 371 kcal/100 g), whereas the isonitrogenous and isocaloric control powder contained 100% L-Alanine (nitrogen, 15.7 wt/wt%; 435 kcal/100 g; provided by Nutricia Nederland BV). The 2 powders were indistinguishable by appearance, color, and smell. During the study period, glutamine and control powder were monitored for stability and microbiological contamination. Between days 3 and 30 of life, supplementation was administered in increasing doses to a maximum of 0.3 g glutamine/kg/d in the glutamine-supplemented group (starting at a dose of 0.05 g/kg/d and increased as soon as possible, depending on the total feeding volume). Initially, the supplementation dose was based on BW. After 2 weeks, the dose was adjusted to actual weight. Two members of the nursing staff added daily supplementation to fortified breast milk or preterm formula (Nenatal, Nutricia Nederland BV). Per 100 mL, the preterm formula provided 78 kcal, 2.1 g protein (casein-whey protein ratio, 40:60), 4.4 g fat, and 7.5 g carbohydrate. The preterm formula did not contain free L-glutamine or alanine. When infants were transferred to other hospitals before the end of the study, the protocol was continued under supervision of the principal investigator (AvdB). 
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Nutritional support. Protocol guidelines for the introduction of parenteral and enteral nutrition followed current practice at our NICU. Administration of parenteral nutrition started at day 2 and was advanced gradually until protein intake reached 2.5 g/kg/d at day 6. Parenteral nutrition was discontinued if enteral feeding reached a volume of approximately 150 mL/kg/d. parenteral nutrition, an all-in-one mixture provided by the hospital pharmacy, contained per 100 mL 54 kcal, 8.5 g glucose, 1.7 g amino acids, and 1.7 g lipids. If necessary, glucose, amino acids, and lipids were given in separate solutions.
Guidelines for the introduction of enteral nutrition were as follows: (1) minimal enteral feeding was started at day 1 (6-12 mL breast milk or preterm formula daily); (2) enteral nutrition was advanced either from day 3 or from day 5 with BW <10th percentile, GA <26 weeks, Apgar score at 5 minutes <6, pH <7.10, or base deficit >10 mmol/L in arterial cord blood; (3) feeding was advanced at a dose of approximately 20 mL/kg/d to a maximum of 150 mL/kg/d or 120 mL/kg/d in infants with fluid restriction. Full enteral feeding was defined as a feeding volume of >120 mL/kg/d. The staff of our NICU had final responsibility for administration of parenteral nutrition and advancement of enteral feeding.
Intestinal permeability. Intestinal permeability was measured by sugar absorption test (SAT), as previously described, 23 at 4 time points: before the start of the study (t = 0), at days 7 (t = 1), 14 (t = 2), and 30 (t = 3) after birth. After instillation of 2 mL/kg of the test solution (100 mg mannitol and 250 mg lactulose/5 mL sterile water) by nasogastric tube, urine was collected for 6 hours. After collection, 0.5 mL chlorohexidine digluconate 20% was added to the urine as a preservative and samples were stored at -20°C until analysis. Lactulose and mannitol concentrations (mmol/mmol creatinine) were measured by gas chromatography 87 and the lactulose/mannitol (L/M) ratio was calculated.
Nutrition and clinical characteristics of the infants at the time of SAT sampling were assessed, including exclusive breast milk feeding, administration of parenteral nutrition, achievement of full enteral feeding, nutritional intake, presence of a serious infection, and administration of dexamethasone or indomethacin. A serious infection was defined as sepsis, meningitis, pyelonephritis, pneumonia, or arthritis as diagnosed by a combination of clinical signs and a positive culture within 48 hours preceding the SAT sampling.
Statistical analysis
The sample size of 102 infants was based on the sample size calculation for the primary outcome of the main trial (time to full enteral feeding) (chapter 2). All infants were considered for assessment of intestinal permeability. Normally distributed and nonparametric data are presented as means (± standard deviations) and medians (ranges), respectively. Perinatal and nutrition characteristics were analyzed with Student's t-test, Mann-Whitney U-test, χ 2 -test, or Fisher's exact test and log rank test for continuous normally distributed data, nonparametric continuous data, dichotomous data, and time-dependent data, respectively.
As parameters of intestinal permeability had a skewed distribution, a logarithmic transformation was performed before analysis. In the primary analysis, generalized estimating equations for longitudinal analysis were used to analyze changes in intestinal permeability over time. 78 This method takes into account the dependency of the observations within a patient and the fact that samples may not be available at each time point. In additional analyses, a correction was made for the age at finishing parenteral nutrition. Furthermore, the effect of exclusive breast milk feeding on intestinal permeability was determined.
All statistical analyses were performed on an intention-to-treat basis. In addition, a per-protocol analysis was performed, excluding all infants who were not treated according to protocol. Non-adherence to protocol was defined as >3 consecutive days or a total of 5 days receiving minimal enteral feeding, or >3 consecutive days or a total of 5 days without supplementation after the start of enteral feeding. A p-value <0.05 (two-tailed) was considered significant. SPSS 11.0 (SPSS Inc, Chicago, IL, USA) and STAT 7.0 (StataCorp LP, College Station, TX, USA) were used for data analysis. 
Results
Between September 2001 and July 2003, 107 of 252 eligible VLBW infants entered the study. Reasons for not participating in the study were: no informed consent (n = 48), participation in another trial (n = 32), transfer from an extraregional hospital (n = 29), transfer to a regional hospital within 48 hours (n = 18), death within 48 hours (n = 12) and severe congenital malformations (n = 6). After randomization, 5 infants with severe congenital malformations were excluded from the study (2 and 3 infants in glutamine-supplemented and control groups, respectively).
Patient characteristics were not different in glutamine-supplemented (n = 52) and control (n = 50) groups, as were nutrition and study supplementation time points (Table 1) . Nutrition and clinical characteristics at the time SATs were performed are presented in Table 2 . Breast milk feeding, nutrition intake, presence of a serious infection, indomethacin or dexamethasone administration were not different in the glutamine-supplemented and control groups. Figure 1 shows the results of the SAT. The age of the infants at successive sampling times was 2.6 ± 0.8 (t = 0), 7.2 ± 0.7 (t = 1), 14.1 ± 0.7 (t = 2), and 30.0 ± 0.6 (t = 3) days after birth. Missing SAT data could mainly be attributed to insufficient urine collections and death of infants. The distribution of missing data did not differ significantly between groups (data not shown). In both groups, the L/M ratio showed a significant decline (p <0.001) from t = 0 (0.18 (0.00-2.10) vs. 0.25 (0.00-1.83) in glutamine-supplemented and control groups, respectively) to t = 3 (0.04 (0.01-0.56) vs. 0.03 (0.00-6.54); Figure 1A ). Analysis by generalized estimating equations showed no effect of glutamine-enriched enteral nutrition on the decrease in L/M ratio. Median urinary lactulose concentrations were lower at t = 1, t = 2, and t = 3 than at t = 0 (p <0.001; Figure 1B) , whereas from t = 0 to t = 3, median urinary mannitol concentrations increased (p = 0.003; Figure 1C ) in both glutamine-supplemented and control groups.
In additional analyses, we found that an adjustment for age at finishing parenteral nutrition did not change the results of the primary analysis. Second, exclusive breast milk feeding did not influence intestinal permeability. Finally, the per-protocol analysis (including 35 and 39 infants in glutamine-supplemented and control groups, respectively) supported the results of the primary analysis. Therefore, we only report the results of the primary analysis.
Discussion
The results of this study in VLBW infants show that glutamine-enriched enteral nutrition between days 3 and 30 of life does not enhance the decrease in intestinal permeability, as assessed by the SAT. As previously published, glutamine 
Time points: before start of the study (t = 0), at days 7 (t = 1), 14 (t =2), and 30 (t = 3) after birth. Generalized estimating equations were used to assess differences between glutamine-supplemented and control groups at baseline and for changes over time (compared with baseline values). A. Urinary lactulose/mannitol ratio. B. Urinary lactulose concentrations. C. Urinary mannitol concentrations.
supplementation did decrease the overall incidence of serious infections in this study (chapter 2). Apparently, this beneficial effect of glutamine-enriched enteral nutrition is not associated with a lower intestinal permeability.
This is the first study into the effect of glutamine-enriched enteral nutrition on intestinal permeability in an unselected group of VLBW infants throughout a 4-week study period. Intestinal permeability, as assessed by the L/M ratio, declined rapidly in the first week of life and remained more or less stable during the remaining 3 weeks. The decline in intestinal permeability was equal in the glutamine-supplemented and control groups. Furthermore, intestinal permeability for lactulose and mannitol was not influenced by breast milk feeding or age at finishing parenteral nutrition. The rapid postnatal decrease of intestinal permeability in this study is in line with other studies in preterm infants. 23, 88 However, Rouwet et al. 89 and Shulman et al. 90 reported an increase in intestinal permeability in preterm infants during the first weeks of life. In these studies, advancement of enteral feeding was postponed until days 7 and 14 of life, respectively, whereas in our study feeding advancement started at day 3 or 5.
In an experimental study of intestinal glutamine deprivation in rats, DeMarco et al. 91 showed that even a low mucosal glutamine concentration was sufficient to support intestinal barrier function, reflected by transepithelial resistance and intestinal permeability. Only complete glutamine depletion (both endogenous and nutritional) resulted in a decrease of intestinal barrier function. It is unlikely that the infants in our study had complete glutamine depletion in the first weeks after birth as minimal enteral feeding was started immediately after birth and enteral nutrition, on average after 3.5 days. These amounts of enteral nutrition during the first days of life probably provide sufficient glutamine to preserve intestinal permeability. Under these circumstances, glutamine-enriched enteral nutrition may have no additional effect on the postnatal decrease in intestinal permeability.
In a landmark study in patients with various gastroenterologic diseases receiving parenteral nutrition, Van der Hulst et al. 22 found that glutamine supplementation prevented deterioration of intestinal permeability and preserved mucosal structure. Recently, the same investigators repeated the study in another group of gastroenterologic patients receiving parenteral nutrition, who were nutritionally depleted.
18 Surprisingly, glutamine supplementation failed to improve intestinal permeability or morphology. The authors attributed the discrepancy to the fact that in the first study subjects mainly had active Crohn's disease or ulcerative colitis, whereas the second study was performed in mostly oncology patients. In addition, patients with significant inflammation were excluded in the second study. Apparently, glutamine supplementation only improves intestinal integrity in patients with both inflammation and nutrition depletion. In another study, Hulsewé et al. 92 confirmed this finding by showing that plasma and mucosal glutamine concentrations, as well as intestinal permeability, were correlated to parameters of inflammation and not to parameters of nutrition depletion. Inflammation has been shown to play an important role in the morbidity of VLBW infants (e.g. chronic lung disease, brain injury). 93, 94 The high intestinal permeability directly after birth and the rapid postnatal decrease may reflect (attenuation of) a neonatal inflammatory response. However, we could not find an additional effect of glutamine-enriched enteral nutrition on this process. This finding may be explained by the fact that in our study the supplementation dose was maximal at approximately day 10 after birth, whereas the largest decrease in intestinal permeability occurred before day 7.
Some remarks may be formulated with regard to the methodology of our study. First, as the sample size calculation was based on the primary outcome of the main trial (chapter 2), the sample size of the study may have been insufficient to detect a difference in intestinal permeability between the glutamine-supplemented and control groups. Second, infants in the control group may have received considerable amounts of glutamine through breast milk. In a study on free amino acids in human milk, Agostoni et al. 95 calculated that a healthy, breast-fed, 1-month-old, 4-kg infant receiving 600 mL human milk per day ingested approximately 120 mg of free glutamine and glutamic acid (0.03 mg/kg/d). The supplementation dose in our study was 0.3 mg/kg/d. Consequently, it is highly improbable that the amount of glutamine ingested by the control group may have approximated that of the glutaminesupplemented group. Third, the L/M ratio values reported in our study are low compared with those in our previous studies. 23, 86 This may be explained by dilution. We found lower values for the L/M ratio by increasing the amount of the preservative chlorohexidine digluconate 20% from 0.1 mL to 0.5 mL per 5 mL urine (data not shown). Fourth, in our previous study, infectious morbidity was defined as ≥1 serious infection during the complete study period. In the current study, we assessed intestinal permeability at 4 time points in the first 30 days of life, and in Table 2 only serious infections within 48 hours preceding SAT sampling are shown. In addition, results of a small number of infants with a serious infection at a SAT sampling day were excluded from analysis because of insufficient urine collection. These factors may explain that we did not find a relation between intestinal permeability and decreased infectious morbidity in VLBW infants receiving glutamine-enriched enteral nutrition. Finally, the passage of saccharides may not adequately reflect the passage of bacteria across the intestinal barrier. 96 In a recent review on intestinal permeability and systemic infections in critically ill adults, de Souza and Greene 97 mentioned several well-designed clinical studies showing an association between increased permeability and systemic infections. One of these studies reported that the higher the increase in intestinal permeability, the higher the risk of infection.
98 These studies at least suggest some causal relationship between increased intestinal permeability and systemic infections.
In conclusion, our study shows that glutamine-enriched enteral nutrition does not enhance the postnatal decrease in intestinal permeability in VLBW infants. The decreased infectious morbidity in VLBW infants receiving glutamine cannot be explained by improved intestinal integrity, as reflected by intestinal permeability. Any beneficial effect of glutamine may involve other aspects of intestinal integrity; for example, modulation of the intestinal inflammatory response.
